Heparina Galenica (Heparin)

Heparina Galenica is indicated for several anticoagulation purposes in adult patients.

• Prevention of deep vein thrombosis (DVT) in patients undergoing surgery or prolonged immobilization.
• Treatment of acute pulmonary embolism to reduce clot burden.
• Anticoagulation during cardiac surgery, including cardiopulmonary bypass.
• Prevention of clot formation in extracorporeal circuits such as dialysis or ECMO.
• Management of other thromboembolic conditions as determined by a physician.
• Bridging anticoagulation therapy when transitioning between oral anticoagulants.

Adverse reactions to Heparina Galenica may vary in frequency and severity.

Common

• Minor bleeding at the injection site.
• Small bruising or hematoma formation.
• Nausea or mild gastrointestinal discomfort.
• Transient elevation of liver enzymes.
• Hypotension due to rapid IV administration.
• Localized pain or irritation at the infusion site.

Serious

• Major hemorrhage requiring medical intervention.
• Heparin-induced thrombocytopenia (HIT).
• Allergic reactions such as urticaria, angioedema, or anaphylaxis.
• Spontaneous spinal or epidural hematoma.
• Osteoporosis with long‑term use.
• Severe thrombocytopenia leading to bleeding complications.

Before initiating Heparina Galenica, clinicians should evaluate several safety considerations to minimize risk.

• Assess baseline coagulation parameters (aPTT, platelet count) and renal function.
• Review patient history for prior heparin exposure or heparin‑induced thrombocytopenia.
• Adjust dose in patients with active bleeding or high bleeding risk.
• Use caution in pregnant or breastfeeding women, as safety data are limited.
• Monitor for signs of bleeding throughout therapy.
• Avoid concurrent use with other anticoagulants unless specifically ordered.
• Consider age‑related dosing adjustments in elderly patients.

Heparina Galenica can interact with other medications, affecting anticoagulant effect or bleeding risk.

Avoid

• Concurrent use with other parenteral anticoagulants (e.g., direct thrombin inhibitors) unless directed.
• Combination with systemic thrombolytic agents (e.g., alteplase).

Use with caution

• Concomitant antiplatelet drugs such as aspirin or clopidogrel.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs) that may increase bleeding.
• Certain antibiotics (e.g., vancomycin) that can potentiate anticoagulation.
• High‑dose corticosteroids that may affect platelet function.